Table 3.
Characteristics of patients with regional lymph node metastases after stereotactic body radiation therapy for cholangiocarcinoma
| Patient | Age/sex | Stage at diagnosis | Primary tumor location | Chemotherapy | SBRT details | Time to LN failure | Location(s) of LN failure |
|---|---|---|---|---|---|---|---|
| 1 | 88/Male | T1N0 | Intrahepatic | None | 45 Gy in 5 fractions | 6 mo | Gastrohepatic, porta hepatis, para-aortic, retrocrural |
| 2 | 80/Male | T2bN1 | Intrahepatic | None | 35 Gy in 5 fractions | 3 mo | Gastrohepatic, para-aortic |
| 3 | 73/Female | T1N0 | Intrahepatic | None | 40 Gy in 5 fractions | 2 mo | Gastrohepatic |
| 4 | 54/Male | T4N1 | Intrahepatic | Adjuvant cisplatin + gemcitabine; cisplatin held due to low blood counts | 42.5 Gy in 5 fractions | 10 mo | Aortocaval, porta hepatis |
| 5 | 86/Male | T4N0 | Extrahepatic | None | 40 Gy in 5 fractions | 5 mo | Aortocaval |
| 6 | 75/Female | T3N0 | Extrahepatic | Adjuvant gemcitabine | 30 Gy in 1 fraction (CyberKnife) | 4 mo | Porta hepatis |
| 7 | 82/Male | T3N1 | Extrahepatic | Adjuvant gemcitabine | 40 Gy in 10 fractions | 7 mo | Gastrohepatic, para-aortic, portal caval |
Abbreviations: LN = lymph node; SBRT = stereotactic body radiation therapy.